DVA

Business profile & competitive position

DaVita Inc. sits in the Healthcare sector’s Medical – Care Facilities industry and operates as one of the largest U.S. providers of kidney dialysis services. As of December 31, 2025, the company ran 2,657 outpatient dialysis centers in the United States serving approximately 200,500 patients, plus another 585 centers across 14 countries serving roughly 94,500 patients. Its core revenue stream is outpatient hemodialysis, but the business also spans hospital inpatient dialysis, home-based dialysis, laboratory services, kidney transplantation support, and integrated kidney-care management. That scale gives DaVita a dense physical network in a service where patients typically visit a center several times per week, which creates high switching costs and makes it difficult for new entrants to replicate the same geographic convenience.

The financial footprint of that moat, however, is mixed. The company reports a net margin of 6.0%, which is positive but thin for a healthcare facility operator; it indicates real operating profitability, yet also shows that reimbursement and labor costs keep a tight lid on pricing power. The more striking figure is ROE of -123.6%. A negative ROE of that magnitude generally signals a negative equity base—often the legacy of years of share buybacks or a leveraged balance sheet—rather than zero earnings. Because net margin is positive, the negative ROE is not evidence of unprofitability; rather, it reflects a highly leveraged capital structure that has shrunk book value. That levers returns when things go well, but it also amplifies risk if reimbursement, interest rates, or operating costs move against the company. The company’s quality record offers some offset: DaVita has been an industry leader in CMS’s Quality Incentive Program for the 11 most recently reported years and in the Five-Star Quality Rating System for the 10 most recently reported years. In a Medicare-regulated field, sustained quality rankings matter because they influence reimbursement rates and patient referrals.

Financial posture

DaVita currently carries an $11.5 billion market capitalization and trades at a P/E of 15.3, putting it near the long-run market average for large-cap healthcare services. The modest P/E, combined with a 6.0% net margin, points to a mature, cash-generative business rather than a high-growth name. Beta is 0.83, meaning the stock historically moves less than the overall market, which is consistent with a defensive, services-heavy healthcare operator whose demand is driven by chronic disease rather than economic cycles.

The negative ROE of -123.6% dominates any snapshot of the balance sheet. Investors interpreting this number should separate profitability from capitalization: DaVita is operationally profitable, but its equity has been driven negative, most likely through aggressive capital returns. That structure can make reported ROE volatile and can limit financial flexibility during periods of rising rates or reimbursement pressure. It also means that traditional book-value-based valuation metrics are essentially useless here. The relevant lens is cash-flow capacity relative to debt service and the stability of the commercial-payer mix, since the company disclosed in its most recent 10-K that nearly all non-hospital dialysis profits come from commercial payors, while government payors cover a much larger share of actual treatments. That payer concentration is a central risk factor embedded in the valuation.

Strategic priorities & outlook

DaVita’s most recent 10-K frames three operational priorities. The first is to “reimagine” kidney care so that it is more preventative, better integrated, outcome-focused, lower-cost, and personalized at scale. The second is to build integrated-care capabilities across the full renal continuum, from chronic kidney disease through end-stage kidney disease to kidney transplant. The third is to support the Comprehensive Kidney Care Contracting model’s goals of delaying disease progression, promoting home dialysis when appropriate, and incentivizing transplants.

Those priorities reveal where management is steering the business: away from a pure fee-for-service dialyzer model and toward a value-based, outcomes-oriented system. That shift matters for margins. U.S. dialysis still represented roughly 86% of consolidated revenues as of December 31, 2025, so reimbursement changes in the Medicare program will continue to move the needle. Meanwhile, international operations are a smaller but deliberate diversification effort, and home dialysis is being pushed as a lower-cost alternative. The 10-K also highlights the dependency on commercial payor profits: even though the U.S. dialysis segment produced the vast majority of revenue, the high-margin economics come from commercial insurance patients. Any strategic plan therefore has to balance growth in patient volume with defense of that commercial mix.

Macro & geopolitical exposure

As a Medical – Care Facilities operator, DaVita’s biggest macro exposures are regulatory and reimbursement-driven rather than cyclical. The dialysis industry is deeply intertwined with Medicare and Medicaid rates set by the Centers for Medicare & Medicaid Services, so changes to reimbursement rules, the ESRD prospective payment system, or quality-based bonus programs can flow directly to margins. The company is also exposed to labor-cost inflation—particularly for nurses and dialysis technicians—because dialysis is labor-intensive and requires specialized staff. Value-based care initiatives such as the Comprehensive Kidney Care Contracting model create policy tailwinds for integrated care but also add administrative complexity and performance risk.

On the international side, currency translation, local reimbursement regimes, and geopolitical stability in the 14 countries where DaVita operates can affect reported results. Supply-chain exposure is moderate; dialysis requires single-use medical supplies, dialyzers, and pharmaceuticals, though most sourcing is not concentrated in geopolitically fragile regions. Trade policy is not a primary driver for this business model, but tariff-related cost pressures on imported medical devices could affect capital-expenditure and supply costs. Overall, the dominant macro risk for the sector is healthcare policy, followed by labor and payer mix.

Recent developments

Recent headlines illustrate a stock that has been moving independently of the broader market. On September 16, 2026, Zacks.com noted that DaVita HealthCare “Advances While Market Declines,” while a separate Benzinga piece the same day highlighted that Warren Buffett and Donald Trump hold bets on the same 17 stocks, with DaVita listed among them. Five days later, on September 21, MarketBeat included DaVita in “3 Surging Stocks That Don’t Need the AI Boom to Keep Winning,” emphasizing its non-tech, services-driven appeal. By September 24, 2026, the tone had flipped: Zacks.com reported that DaVita HealthCare “Registers a Bigger Fall Than the Market,” underscoring short-term volatility even in a low-beta name.

That sequence—outperformance, inclusion in a “no-AI-needed” basket, then underperformance in the same two-week window—fits a stock where headline sentiment is being reset by earnings expectations and reimbursement/policy headlines rather than by broad economic data. The Berkshire ownership angle also keeps the name on value-oriented watchlists.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, DaVita has beaten earnings estimates six times, for a 75% beat rate, with an average earnings surprise of 2.3%. The average five-day price move after those reports is 6.36% to the upside, which would normally suggest a healthy post-earnings drift. But the headline average masks real dispersion, and the most instructive feature of DaVita’s recent earnings behavior is how unreliable the “beat = pop” assumption has been.

In the most recent four quarters, DaVita beat estimates three times and missed once. The August 4, 2026 report showed an EPS beat of 3.6% ($4.02 actual versus $3.88 estimate), yet the stock fell 17.24% the next day and 21.78% over the following five sessions. That is a stark disconnect: the company cleared the published consensus but the market responded as if guidance or underlying trends had deteriorated. Reforecast risk, commercial payer mix concerns, or a re-rating of long-term reimbursement expectations are the usual culprits in such cases.

The two preceding quarters delivered the more intuitive pattern. On May 5, 2026, DaVita beat by 19.1% ($2.87 versus $2.41) and the stock rallied 23.46% the next day, extending to a 27.7% five-day gain. On February 2, 2026, a 4.9% beat ($3.40 versus $3.24) produced a 21.17% one-day jump and a 23.79% five-day gain. Those moves were large, but they were driven partly by low starting expectations rather than by smooth drift. The October 29, 2025 quarter was the miss: EPS came in at $2.51 versus an estimate of $3.17, a -20.8% surprise, and the stock fell 6.17% the next day and 4.27% over five days.

The takeaway is that DaVita’s post-earnings moves are asymmetric and sometimes de-coupled from the headline surprise. A 75% beat rate and a positive average drift are useful summary statistics, but they do not guarantee that any single beat will be rewarded. With the next report scheduled for November 4, 2026 after the close and the consensus EPS estimate at $3.55, the market will likely focus at least as much on forward commentary and payer-mix guidance as on the printed number.

For a deeper view of how sell-side analysts and institutional models are positioned ahead of the November report, readers should review the full institutional verdict on the platform.